Klebsiella granulomatis

From WikiMD's WELLNESSPEDIA

Klebsiella granulomatis is a bacterial species in the Klebsiella genus of the Enterobacteriaceae family. It is the causative agent of granuloma inguinale, a sexually transmitted infection.

Taxonomy[edit]

The bacterium was first described in 1913 by Charles Donovan, and was initially named Donovanosis granulomatis. It was later reclassified into the Klebsiella genus due to its similar characteristics with other species in this genus.

Characteristics[edit]

Klebsiella granulomatis is a Gram-negative, rod-shaped bacterium. It is non-motile and does not form spores. The bacterium is oxidase negative and catalase positive.

Pathogenesis[edit]

Klebsiella granulomatis causes granuloma inguinale, a chronic and progressive sexually transmitted infection. The bacterium infects the skin and mucous membranes, leading to the formation of granulomatous lesions. The disease is most common in tropical and subtropical regions.

Diagnosis[edit]

Diagnosis of granuloma inguinale is typically made by identifying Klebsiella granulomatis in tissue samples from the lesions. The bacterium can be visualized using Wright's stain or Giemsa stain.

Treatment[edit]

Treatment for granuloma inguinale typically involves antibiotics, such as doxycycline or azithromycin. Early treatment can prevent complications, such as scarring and genital mutilation.

Epidemiology[edit]

Granuloma inguinale is rare in most parts of the world, but is more common in certain tropical and subtropical regions, including parts of India, Papua New Guinea, and the Caribbean.

See also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.